These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 10992722)

  • 1. The relationship between virological characteristics of hepatitis C virus (HCV) and reactivity to the regional specific proteins of HCV.
    Yoon SK; Park YM; Byun BH; Bae SH; Yang JM; Ahn BM; Lee YS; Lee CD; Sun HS; Kim BS
    Korean J Intern Med; 2000 Jul; 15(2):109-16. PubMed ID: 10992722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative antibody responses to structural (Core) and nonstructural (NS3, NS4, and NS5) hepatitis C virus proteins among seroconverting injecting drug users: impact of epitope variation and relationship to detection of HCV RNA in blood.
    Beld M; Penning M; van Putten M; Lukashov V; van den Hoek A; McMorrow M; Goudsmit J
    Hepatology; 1999 Apr; 29(4):1288-98. PubMed ID: 10094977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatitis C virus replication and antibody responses toward specific hepatitis C virus proteins.
    Yuki N; Hayashi N; Kasahara A; Hagiwara H; Ohkawa K; Fusamoto H; Kamada T
    Hepatology; 1994 Jun; 19(6):1360-5. PubMed ID: 7514560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequential changes of hepatitis C virus antibody profiles during treatment of chronic hepatitis C of genotype 1b: pretreatment antibody response to E2/NS1 correlated sustained response.
    Chu CM; Sheen IS; Liaw YF
    Infection; 2004 Jun; 32(3):153-6. PubMed ID: 15188075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in hepatitis C virus (HCV) antibody status in patients with chronic hepatitis C after eradication of HCV infection by interferon therapy.
    Toyoda H; Kumada T; Kiriyama S; Sone Y; Tanikawa M; Hisanaga Y; Kuzuya T; Honda T; Hayashi K; Nakano I; Katano Y; Goto H
    Clin Infect Dis; 2005 Mar; 40(6):e49-54. PubMed ID: 15736006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relation between reactivity to the NS-4 region peptides of hepatitis C virus (HCV) and clinical features among patients infected with HCV genotype 1b.
    Sakugawa H; Nakasone H; Nakayoshi T; Kawakami Y; Kinjo F; Saito A; Nakayoshi T; Yamashiro A
    Microbiol Immunol; 1998; 42(4):299-303. PubMed ID: 9623917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monitoring antibody titers to recombinant Core-NS3 fusion polypeptide is useful for evaluating hepatitis C virus infection and responses to interferon-alpha therapy.
    Park YM; Byun BH; Choi JY; Bae SH; Kim BS; So HS; Ryu WS
    J Korean Med Sci; 1999 Apr; 14(2):165-70. PubMed ID: 10331562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-level hepatitis C viremia and humoral immune response to NS4 in chronic hepatitis B virus-hepatitis C virus coinfection.
    Chu CM; Sheen IS; Liaw YF
    Scand J Gastroenterol; 2004 Aug; 39(8):778-82. PubMed ID: 15513365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Significance of highly positive c22-3 "indeterminate" second-generation hepatitis C virus (HCV) recombinant immunoblot assay (RIBA) and resolution by third-generation HCV RIBA.
    Pawlotsky JM; Fleury A; Choukroun V; Deforges L; Roudot-Thoraval F; Aumont P; Duval J; Dhumeaux D
    J Clin Microbiol; 1994 May; 32(5):1357-9. PubMed ID: 7519631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of the antibody reactivity to synthetic peptides from different parts of the hepatitis C virus genome.
    Pujol FH; Khudyakov YE; Devesa M; León G; Blitz-Dorfman L; Monsalve F; Lambert SB; Kalinina TY; Liprandi F; Fields HA
    Viral Immunol; 1996; 9(2):89-96. PubMed ID: 8822625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Significance of indeterminate third-generation hepatitis C virus recombinant immunoblot assay.
    Pawlotsky JM; Bastie A; Pellet C; Remire J; Darthuy F; Wolfe L; Sayada C; Duval J; Dhumeaux D
    J Clin Microbiol; 1996 Jan; 34(1):80-3. PubMed ID: 8748278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antigenic variation of core, NS3, and NS5 proteins among genotypes of hepatitis C virus.
    Neville JA; Prescott LE; Bhattacherjee V; Adams N; Pike I; Rodgers B; El-Zayadi A; Hamid S; Dusheiko GM; Saeed AA; Haydon GH; Simmonds P
    J Clin Microbiol; 1997 Dec; 35(12):3062-70. PubMed ID: 9399495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in antibodies to specific hepatitis C virus antigens with interferon-alpha therapy: analysis by recombinant immunoblot assay.
    Yuki N; Hayashi N; Hagiwara H; Takehara T; Katayama K; Kasahara A; Fusamoto H; Kamada T
    Am J Gastroenterol; 1993 Jun; 88(6):914-8. PubMed ID: 7684885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis C virus markers in patients with long-term biochemical and histological remission of chronic hepatitis.
    Saracco G; Abate ML; Baldi M; Calvo PL; Manzini P; Brunetto MR; Oliveri F; Kuo G; Chien D; Houghton M
    Liver; 1994 Apr; 14(2):65-70. PubMed ID: 7515141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Second generation hepatitis-C virus test and polymerase chain reaction in anti-C 100 negative patients with chronic non-A, non-B hepatitis].
    Zala G; Havelka J; Wicki AN; Joller-Jemelka HI; Meier B; Schmid M; Bühler H
    Schweiz Med Wochenschr; 1992 Mar; 122(11):363-8. PubMed ID: 1313601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis C virus infection in children with hemophilia: characterization of antibody response to four different antigens and relationship of antibody response, viremia, and hepatic dysfunction.
    Kanesaki T; Kinoshita S; Tsujino G; Yoshioka K; Ikegami N
    J Pediatr; 1993 Sep; 123(3):381-7. PubMed ID: 7689096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis C virus genotypes, reactivity to recombinant immunoblot assay 2 antigens and liver disease.
    Ichimura H; Tamura I; Kurimura O; Koda T; Mizui M; Tsuchie H; Kurimura T
    J Med Virol; 1994 Jul; 43(3):212-5. PubMed ID: 7523579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis C virus serotype-specific core and NS4 antibodies in injecting drug users participating in the Amsterdam cohort studies.
    Beld M; Penning M; van Putten M; van den Hoek A; Lukashov V; McMorrow M; Goudsmit J
    J Clin Microbiol; 1998 Oct; 36(10):3002-6. PubMed ID: 9738057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis C viral clearance and antibody reactivity patterns in persons with haemophilia and other congenital bleeding disorders.
    Messick K; Sanders JC; Goedert JJ; Eyster ME
    Haemophilia; 2001 Nov; 7(6):568-74. PubMed ID: 11851755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-envelope 1 and 2 immune response in chronic hepatitis C patients: effects of hepatitis B virus co-infection and interferon treatment.
    Zampino R; Marrone A; Durante Mangoni E; Santarpia L; Sica A; Tripodi MF; Utili R; Ruggiero G; Adinolfi LE
    J Med Virol; 2004 May; 73(1):33-7. PubMed ID: 15042645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.